Search results
Results from the WOW.Com Content Network
[19] [13] [49] [47] [50] [51] Brain MAO-B levels recover slowly upon discontinuation of selegiline, with a half-time of brain MAO-B synthesis and recovery of approximately 40 days in humans. [19] [48] Selegiline inhibits MAO-B by 50% at a very low concentration of 26 pg/mL in vivo, indicating that it is a very potent MAO-B inhibitor. [36]
Moclobemide is a benzamide, [13] derivative of morpholine, [98] which acts pharmacologically as a selective, reversible inhibitor of monoamine oxidase-A (RIMA), [10] a type of monoamine oxidase inhibitor (MAOI), and increases levels of norepinephrine (noradrenaline), dopamine, and especially serotonin [9] [99] in neuronal cells as well as in ...
Selegiline acts as a monoamine oxidase inhibitor (MAOI) and thereby increases levels of monoamine neurotransmitters in the brain. [17] [11] [28] [5] At typical clinical doses used for Parkinson's disease, selegiline is a selective and irreversible inhibitor of monoamine oxidase B (MAO-B), increasing brain levels of dopamine.
Monoamine oxidase inhibitors, or MAOIs, including phenelzine, isocarboxazid, tranylcypromine, selegiline and others. Other antidepressants, including other SSRIs, SNRIs and tricyclic antidepressants
Therefore, reducing MAO-B results in higher quantities of L-DOPA in the striatum. [3] Similarly to dopamine agonists, MAO-B inhibitors improve motor symptoms and delay the need of taking levodopa when used as monotherapy in the first stages of the disease, but produce more adverse effects and are less effective than levodopa.
The older MAOIs' heyday was mostly between the years 1957 and 1970. [43] The initial popularity of the 'classic' non-selective irreversible MAO inhibitors began to wane due to their serious interactions with sympathomimetic drugs and tyramine-containing foods that could lead to dangerous hypertensive emergencies. As a result, the use by medical ...
Rasagiline acts as an inhibitor of the enzyme monoamine oxidase (MAO) and hence is a monoamine oxidase inhibitor (MAOI). [2] More specifically, it is a selective inhibitor of monoamine oxidase B (MAO-B). [2] The drug is thought to work by increasing levels of the monoamine neurotransmitter dopamine in the brain. [2]
Tranylcypromine, sold under the brand name Parnate among others, [1] is a monoamine oxidase inhibitor (MAOI). [4] [7] More specifically, tranylcypromine acts as nonselective and irreversible inhibitor of the enzyme monoamine oxidase (MAO).